Effect of Various Absorption Enhancers Based on Tight Junctions on the Intestinal Absorption of Forsythoside A in Shuang-Huang-Lian, Application to Its Antivirus Activity

Overview

Journal Pharmacogn Mag

Publisher Sage Publications

Date 2014 Apr 4

PMID 24695554

Citations 6

Authors

Wei Zhou

Xuan Xuan Zhu

Ai Ling Yin

Bao Chang Cai

Hai Dan Wang

Liuqing Di

Jin Jun Shan

Affiliations

Soon will be listed here.

Abstract

Background: Forsythoside A (FTA), one of the main active ingredients in Shuang-Huang-Lian (SHL), possesses strong antibacterial, antioxidant and antiviral effects, and its pharmacological effects was higher than that of other ingredients, but the absolute bioavailability orally was approximately 0.72%, which was significantly low, influencing clinical efficacies of its oral preparations seriously.

Materials And Methods: In vitro Caco-2 cell and in vivo pharmacokinetics study were simultaneously performed to investigate the effects of absorption enhancers based on tight junctions: sodium caprate and water-soluble chitosan on the intestinal absorption of FTA, and the eventual mucosal epithelial damage resulted from absorption enhancers was evaluated by MTT test and morphology observation, respectively. The pharmacological effects such as antivirus activity improvement by absorption enhancers were verified by MDCK damage inhibition rate after influenza virus propagation.

Results: The observations from in vitro Caco-2 cell showed that the absorption of FTA in SHL could be improved by absorption enhancers. Meanwhile, the absorption enhancing effect of water-soluble chitosan may be almost saturable up to 0.0032% (w/v), and sodium caprate at concentrations up to 0.64 mg/mL was safe, but water-soluble chitosan at different concentrations was all safe for these cells. In pharmacokinetics study, water-soluble chitosan at dosage of 50 mg/kg improved the bioavailability of FTA in SHL to the greatest extent, and was safe for gastrointestine from morphological observation. Besides, treatment with SHL with water-soluble chitosan at dosage of 50 mg/kg prevented MDCK damage after influenza virus propagation better significantly than that of control.

Conclusion: Water-soluble chitosan at dosage of 50 mg/kg might be safe and effective absorption enhancer for improving the bioavailability of FTA and the antivirus activity in vitro in SHL.

Citing Articles

Effects of Three Kinds of Carbohydrate Pharmaceutical Excipients-Fructose, Lactose and Arabic Gum on Intestinal Absorption of Gastrodin through Glucose Transport Pathway in Rats.

Chen Z, Chen J, Wang L, Wang W, Zheng J, Wu S Pharm Res. 2024; 41(6):1201-1216.

PMID: 38834905 DOI: 10.1007/s11095-024-03720-3.

Influence of Chitosan Nanoparticles as the Absorption Enhancers on Salvianolic acid B In vitro and In vivo Evaluation.

Jin X, Zhang S, Li S, Liang K, Jia Z Pharmacogn Mag. 2016; 12(45):57-63.

PMID: 27019562 PMC: 4787338. DOI: 10.4103/0973-1296.176047.

Discovery and Current Status of Evaluation System of Bioavailability and Related Pharmaceutical Technologies for Traditional Chinese Medicines--Flos Lonicerae Japonicae--Fructus Forsythiae Herb Couples as an Example.

Zhou W, Cai B, Shan J, Wang S, Di L Int J Mol Sci. 2015; 16(12):28812-40.

PMID: 26690115 PMC: 4691079. DOI: 10.3390/ijms161226132.

Pharmacokinetics, intestinal absorption and microbial metabolism of single platycodin D in comparison to Platycodi radix extract.

Shan J, Zou J, Xie T, Kang A, Zhou W, Deng H Pharmacogn Mag. 2015; 11(44):750-5.

PMID: 26600720 PMC: 4621644. DOI: 10.4103/0973-1296.165576.

Using Bioinformatics Approach to Explore the Pharmacological Mechanisms of Multiple Ingredients in Shuang-Huang-Lian.

Zhang B, Li J, Gu H, Li Q, Zhang Q, Zhang T ScientificWorldJournal. 2015; 2015:291680.

PMID: 26495421 PMC: 4606080. DOI: 10.1155/2015/291680.

References

Zhou W, DI L, Wang J, Shan J, Liu S, Ju W . Intestinal absorption of forsythoside A in in situ single-pass intestinal perfusion and in vitro Caco-2 cell models. Acta Pharmacol Sin. 2012; 33(8):1069-79. PMC: 4011322. DOI: 10.1038/aps.2012.58. View

Shi Y, Shi R, Liu B, Lu Y, Du L . [Isolation and elucidation of chemical constituents with antiviral action from yinqiaosan on influenza virus]. Zhongguo Zhong Yao Za Zhi. 2004; 28(1):43-7. View

Li Y, Zhang M, Wang J, Zhang S, Liu J, Zhang Q . [Effects of absorption enhancers on intestinal absorption of lumbrokinase]. Yao Xue Xue Bao. 2006; 41(10):939-44. View

Wang L, Wang Z, Wo S, Lau C, Chen X, Huang M . A bio-activity guided in vitro pharmacokinetic method to improve the quality control of Chinese medicines, application to Si Wu Tang. Int J Pharm. 2011; 406(1-2):99-105. DOI: 10.1016/j.ijpharm.2011.01.001. View

Li Y, Peng C, Ye L, Zhang R, Jiang X . Investigation on the absorption of phillyrin and forsythiaside in rat digestive tract. Eur J Drug Metab Pharmacokinet. 2011; 36(2):79-85. DOI: 10.1007/s13318-011-0031-3. View

Ye J, Wei W, Quan L, Liu C, Chang Q, Liao Y . An LC-MS/MS method for the simultaneous determination of chlorogenic acid, forsythiaside A and baicalin in rat plasma and its application to pharmacokinetic study of shuang-huang-lian in rats. J Pharm Biomed Anal. 2010; 52(4):625-30. DOI: 10.1016/j.jpba.2010.01.035. View

Zhao Y, Li F, Yang J, An X, Zhou M . [Effect of phillyrin on the anti-obesity in nutritive obesity mice]. Zhong Yao Cai. 2005; 28(2):123-4. View

Diaz Lanza A, Abad Martinez M, Fernandez Matellano L, Recuero Carretero C, Villaescusa Castillo L, Silvan Sen A . Lignan and phenylpropanoid glycosides from Phillyrea latifolia and their in vitro anti-inflammatory activity. Planta Med. 2001; 67(3):219-23. DOI: 10.1055/s-2001-12004. View

Jin X, Zhang Z, Sun E, Tan X, Zhu F, Li S . Preparation of icariside II-phospholipid complex and its absorption across Caco-2 cell monolayers. Pharmazie. 2012; 67(4):293-8. View

10.

Thanou M, Nihot M, Jansen M, Verhoef J, Junginger H . Mono-N-carboxymethyl chitosan (MCC), a polyampholytic chitosan derivative, enhances the intestinal absorption of low molecular weight heparin across intestinal epithelia in vitro and in vivo. J Pharm Sci. 2000; 90(1):38-46. DOI: 10.1002/1520-6017(200101)90:1<38::aid-jps5>3.0.co;2-3. View

11.

Lindmark T, Kimura Y, Artursson P . Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells. J Pharmacol Exp Ther. 1998; 284(1):362-9. View

12.

Thanou M, Henderson S, Kydonieus A, Elson C . N-sulfonato-N,O-carboxymethylchitosan: a novel polymeric absorption enhancer for the oral delivery of macromolecules. J Control Release. 2006; 117(2):171-8. DOI: 10.1016/j.jconrel.2006.11.002. View

13.

Gao Y, He L, Katsumi H, Sakane T, Fujita T, Yamamoto A . Improvement of intestinal absorption of insulin and water-soluble macromolecular compounds by chitosan oligomers in rats. Int J Pharm. 2008; 359(1-2):70-8. DOI: 10.1016/j.ijpharm.2008.03.016. View

14.

Bernkop-Schnurch A . Chitosan and its derivatives: potential excipients for peroral peptide delivery systems. Int J Pharm. 1999; 194(1):1-13. DOI: 10.1016/s0378-5173(99)00365-8. View

15.

Konishi Y, Kobayashi S . Transepithelial transport of chlorogenic acid, caffeic acid, and their colonic metabolites in intestinal caco-2 cell monolayers. J Agric Food Chem. 2004; 52(9):2518-26. DOI: 10.1021/jf035407c. View

16.

Illum L, Farraj N, Davis S . Chitosan as a novel nasal delivery system for peptide drugs. Pharm Res. 1994; 11(8):1186-9. DOI: 10.1023/a:1018901302450. View

17.

Motlekar N, Srivenugopal K, Wachtel M, Youan B . Oral delivery of low-molecular-weight heparin using sodium caprate as absorption enhancer reaches therapeutic levels. J Drug Target. 2006; 13(10):573-83. PMC: 1993550. DOI: 10.1080/10611860500471906. View

18.

Qu H, Zhang Y, Wang Y, Li B, Sun W . Antioxidant and antibacterial activity of two compounds (forsythiaside and forsythin) isolated from Forsythia suspensa. J Pharm Pharmacol. 2008; 60(2):261-6. DOI: 10.1211/jpp.60.2.0016. View

19.

Han J, Ye M, Guo H, Yang M, Wang B, Guo D . Analysis of multiple constituents in a Chinese herbal preparation Shuang-Huang-Lian oral liquid by HPLC-DAD-ESI-MSn. J Pharm Biomed Anal. 2007; 44(2):430-8. DOI: 10.1016/j.jpba.2007.02.023. View